Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

[ad_1] – Alar’s Lead Asset ALA-1000 Potentially is the First Three-Month LAI Treatment for OUD – RICHMOND, Va., Oct. 11, 2023 /PRNewswire/ — Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company,…

London markets inch lower as housing firms drive drop

[ad_1] T he FTSE 100 looked set to post its first rise for more than a week on Monday but lost all its steam to finish in the red due…